<DOC>
	<DOCNO>NCT01245855</DOCNO>
	<brief_summary>hypothesize periprocedural treatment intravenous lipo-PGE1 may reduce myocardial injury improve clinical outcome patient undergo PCI .</brief_summary>
	<brief_title>Protective Effect Lipo-PGE1 Myocardial Injury Following Percutaneous Coronary Intervention</brief_title>
	<detailed_description>Ever since inception percutaneous coronary intervention ( PCI ) , apparent myocardial injury often associated procedure , even asymptomatic minor post-procedural myocardial necrosis important prognostic signification . The possible mechanisms periprocedural myocardial injury often attribute distal embolisation atheromatous material procedure , occlusion minute side branch , occlusive dissection no-reflow . Prostaglandin E1 incorporate lipid microspheres ( lipo-PGE1 ) new galenic form PGE1 , PGE1 incorporate soybean oil microspheres 0.2 micron diameter , use lecithin surfactant . This drug preparation protect PGE1 inactivation lung target effect tissue injure arterial occlusion . It show experiment , pharmacological effect improve endothelial function , dilate coronary systemic microvessels , inhibit platelet aggregation reduce ischemia-reperfusion injury , lipo-PGE1 mark protective effect arterial occlusive tissue injury potent platelet aggregation inhibitory effect free PGE1 . Clinical study demonstrate lipo-PGE1 valuable agent treatment peripheral vascular disorder diabetic neuropathy .</detailed_description>
	<mesh_term>Alprostadil</mesh_term>
	<criteria>presence nonSTsegment elevation acute coronary syndrome ( unstable angina nonSTsegment elevation acute myocardial infarction ) send early PCI ( within 72h onset symptom ) STsegment elevation acute myocardial infarction , nonSTsegment elevation acute coronary syndrome highrisk feature warrant emergency invasive approach , leave ventricular ejection fraction &lt; 35 % , previous revascularization , renal failure creatinine &gt; 3 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Prostaglandin E1</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>Cardiac troponin T</keyword>
	<keyword>Creatine kinase-MB</keyword>
</DOC>